Comparative Pharmacology
Head-to-head clinical analysis: AJOVY versus NURTEC ODT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AJOVY versus NURTEC ODT.
AJOVY vs NURTEC ODT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ajovy (fremanezumab) is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) and blocks its binding to the CGRP receptor, thereby inhibiting CGRP-mediated neurogenic vasodilation and pain transmission in trigeminal sensory neurons.
CGRP receptor antagonist; blocks binding of calcitonin gene-related peptide to its receptor, inhibiting vasodilation and neurogenic inflammation in trigeminovascular system.
AJOVY (fremanezumab-vfrm) is administered subcutaneously at a dose of 675 mg once every 3 months (quarterly) or 225 mg once monthly. The injection volume is 1.5 mL for the 225 mg dose and 4.5 mL for the 675 mg dose, administered as three separate injections of 225 mg each.
75 mg orally once daily as needed, not to exceed 75 mg in 24 hours.
None Documented
None Documented
Terminal elimination half-life is 31 days (range 23-37 days). This long half-life supports monthly subcutaneous dosing.
Terminal elimination half-life of approximately 11 hours, supporting twice-daily dosing for migraine prevention.
Renal excretion of intact antibody is minimal; metabolized via catabolism to peptides and amino acids. Approximately 100% of elimination is via intracellular degradation (proteolysis) and biliary excretion of metabolites, with negligible renal excretion.
Roughly 75% of dose excreted in feces (as unchanged drug and metabolites), 24% in urine (mostly metabolites, <1% unchanged).
Category C
Category C
CGRP Antagonist
CGRP Antagonist